Immunovant annual total assets
2019
2020
2021
2022
2023
2024
2025
2026
Immunovant Total Assets Growth & History (IMVT)
Immunovant's total assets was $957.0M for fiscal 2026.
View full Immunovant company overviewImmunovant annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $957.0M | $180.8M | +23.29% |
| 2025 | 2025-03-31 | $776.2M | $109.9M | +16.49% |
| 2024 | 2024-03-31 | $666.4M | $260.5M | +64.19% |
| 2023 | 2023-03-31 | $405.8M | −$109.7M | −21.28% |
| 2022 | 2022-03-31 | $515.6M | $103.1M | +24.99% |
| 2021 | 2021-03-31 | $412.5M | $303.1M | +277.09% |
| 2020 | 2020-03-31 | $109.4M | $95.6M | +691.05% |
| 2019 | 2019-03-31 | $13.8M | — | — |
Immunovant quarterly total assets
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $852.5M | $191.1M | +28.88% |
| Q4 2026 | 2026-03-31 | $957.0M | $180.8M | +23.29% |
| Q3 2026 | 2025-12-31 | $1.05B | $631.5M | +150.01% |
| Q2 2026 | 2025-09-30 | $583.0M | $67.3M | +13.04% |
| Q1 2026 | 2025-06-30 | $661.4M | $71.8M | +12.17% |
| Q4 2025 | 2025-03-31 | $776.2M | $109.9M | +16.49% |
| Q3 2025 | 2024-12-31 | $420.9M | −$290.5M | −40.83% |
| Q2 2025 | 2024-09-30 | $515.7M | $223.6M | +76.57% |
| Q1 2025 | 2024-06-30 | $589.7M | $238.5M | +67.89% |
| Q4 2024 | 2024-03-31 | $666.4M | $260.5M | +64.19% |
| Q3 2024 | 2023-12-31 | $711.4M | $255.2M | +55.94% |
| Q2 2024 | 2023-09-30 | $292.1M | −$136.1M | −31.78% |
| Q1 2024 | 2023-06-30 | $351.2M | −$107.4M | −23.42% |
| Q4 2023 | 2023-03-31 | $405.8M | −$109.7M | −21.28% |
| Q3 2023 | 2022-12-31 | $456.2M | −$86.9M | −16.01% |
| Q2 2023 | 2022-09-30 | $428.1M | −$138.6M | −24.45% |
| Q1 2023 | 2022-06-30 | $458.7M | $70.6M | +18.20% |
| Q4 2022 | 2022-03-31 | $515.6M | $103.1M | +24.99% |
| Q3 2022 | 2021-12-31 | $543.2M | $110.2M | +25.44% |
| Q2 2022 | 2021-09-30 | $566.7M | $112.8M | +24.86% |
| Q1 2022 | 2021-06-30 | $388.0M | $97.7M | +33.67% |
| Q4 2021 | 2021-03-31 | $412.5M | $303.1M | +277.09% |
| Q3 2021 | 2020-12-31 | $433.0M | $306.4M | +241.99% |
| Q2 2021 | 2020-09-30 | $453.9M | $336.1M | +285.35% |
| Q1 2021 | 2020-06-30 | $290.3M | $172.9M | +147.23% |
| Q4 2020 | 2020-03-31 | $109.4M | $95.6M | +691.05% |
| Q3 2020 | 2019-12-31 | $126.6M | — | — |
| Q2 2020 | 2019-09-30 | $117.8M | — | — |
| Q1 2020 | 2019-06-30 | $117.4M | — | — |
| Q4 2019 | 2019-03-31 | $13.8M | — | — |
Immunovant total assets trends
Over the last five fiscal years, Immunovant's total assets increased from $412.5M to $957.0M, a change of $544.5M. The latest reported quarter, Q1 2027, shows $852.5M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunovant source filings ↗